Raw Flibanserin powder (167933-07-5) video
Raw Flibanserin powder (167933-07-5)
Raw Flibanserin powder, sold under the trade name Addyi, is a multifunctional serotonin agonist and antagonist which is used for the treatment of pre-menopausal women with hypoactive sexual desire disorder (HSDD). The medication increases the number of satisfying sexual events per month by about one half over placebo from a starting point of about two to three. At the same time, It has a role as a serotonergic agonist, a serotonergic antagonist and an antidepressant..
Raw Flibanserin powder (167933-07-5) Specifications
|Product Name||Raw Flibanserin powder|
|Drug Class||Multifunctional serotonin agonist and antagonist|
|Molecular Weight||390.41 g/mol|
|Monoisotopic Mass||390.167 g/mol|
|Biological Half-Life||~11 hours|
|Color||White to beige|
|Solubility||DMSO: soluble10mg/mL, clear|
|Raw Flibanserin powder Application||Developed for the treatment of hypoactive sexual desire disorder in women|
Raw Flibanserin powder (167933-07-5) Description
Flibanserin powder is the first drug to be approved for hypoactive sexual desire disorder (HSDD) in premenopausal women by the FDA in August 2015. It was originally developed as an antidepressant medication by Boehringer Ingelheim, but showed lack of efficacy in trials and was further developed as a hypoactive sexual disorder drug by Sprout Pharmaceuticals. Flibanserin’s mechanism of action is attributed to its high affinity for 5-HTA1 and 5-HTA2 receptors, displaying agonist activity on 5-HTA1 and antagonist on 5-HTA2, resulting in lowering of serotonin in the brain as well as an effect on increasing norepinephrine and dopamine neurotransmitters.
Flibanserin powder (167933-07-5) Mechanism of Action
Flibanserin’s mechanism of action is attributed to its high affinity for 5-HTA1 and 5-HTA2 receptors, displaying agonist activity on 5-HTA1 and antagonist on 5-HTA2, resulting in lowering of serotonin in the brain as well as an effect on increasing norepinephrine and dopamine neurotransmitters. Flibansetrin has high affinity for serotonin receptors in the brain: it acts as an agonist on 5-HT1A and an antagonist on 5-HT2A. In vivo, flibanserin binds equally to 5-HT1A and 5-HT2A receptors. However, under higher levels of brain 5-HT (i.e., under stress), flibanserin may occupy 5-HT2A receptors in higher proportion than 5-HT(1A) receptors. It may also moderately antagonize D4 (dopamine) receptors and 5-HT2B and 5-HTB2C. Its action on neurotransmitter receptors may contribute to reduction in serotonin levels and increase in dopamine and norepinephrine levels, all of which may play part in reward processing. Flibanserin is sold under the trade name Addyi and indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD) as characterized by low sexual desire that causes marked distress or interpersonal difficulty.
Application of Flibanserin powder (167933-07-5)
Flibanserin powder is a 5-HT1A agonist and 5-HT2A antagonist that is developed for the treatment of hypoactive sexual desire disorder in women (1,2).
Recommended Flibanserin powder (167933-07-5) Dosage
100 mg orally once per day at bedtime
Duration of therapy: This drug should be discontinued after 8 weeks if the patient does not report an improvement in symptoms.
Comments: This drug is not indicated to enhance sexual performance, and is not indicated for treatment in postmenopausal women or in men.
Side effects of Flibanserin powder (167933-07-5)
Adverse events are more common among women taking flibanserin powder. The majority of adverse events were mild to moderate. The most commonly reported adverse events included dizziness, nausea, feeling tired, sleepiness, and trouble sleeping.
Drinking alcohol while on flibanserin powder may result in severely low blood pressure (low blood pressure that produced symptoms after 2 glasses of wine occurred in 17%).